drugset
drugset / Trial / NCT01709292

Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer

NCT01709292 ↗

Phase 2 Active not recruiting 24 enrolled M.D. Anderson Cancer Center Genentech, Inc. · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to learn about how vemurafenib may affect certain biomarkers in patients with PTC. Biomarkers are in the blood/tissue and may be related to your reaction to the study drug. The safety of this drug will also be studied. Vemurafenib is designed to block the BRAF gene mutation. This mutation causes cancer and cancer growth. By blocking this mutation, the drug may kill the cancer cells with the mutation and/or stop the tumor from growing.

Timeline

Start
2012-11-07
Primary completion
2026-09-30
Completion
2026-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Vemurafenib Small molecule 960 mg Oral

Indications

thyroid cancer